AzTrials
AzTrials

Type1diabetesSTEPP-UPNCT04550585

Specialized Technology Education for Pumps & Pens in Underserved Populations With Diabetes

An observational study of Type1diabetes, run by University of Southern California at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Lower socioeconomic status (SES) individuals with type 1 diabetes have poorer outcomes than wealthier patients and part of this disparity comes from a lack of tools and knowledge about how to teach these patients on the technologies other patients take for granted. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Type1diabetes
What is being tested?
Education: Session 1 - Basics of type 1 management, Session 2 - Carbohydrate counting and Education: Session 3 - Insulin self- adjustment
How many people
63 participants
Where
1 siteUnited States
Study dates
1 Apr 2017to 31 Jul 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Adult, Older adult

Study population: English or Spanish speaking adults ages 18 to 75 with type 1 diabetes

Who may be able to join

  • Diagnosis of type 1 diabetes
  • Age 18 - 75 years old
  • Currently being treated at the T1D clinic in the LAC/USC Healthcare System
  • No use of CSII or insulin pen in the past 6 months
  • No serious illnesses where life expectancy is <1 year
  • Understand the study requirements and agree to comply with all study visits and procedures.
  • Fluent in English or Spanish

Who cannot join

  • Subject is currently pregnant or lactating or plan on becoming pregnant during the course of the study.
  • Subject is Blind
  • Subject cannot follow instructions due to a medical condition or mental illness.
  • Subject has a known allergy to medical adhesive.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Southern California Eastside Center for Diabetes

    Los Angeles, California, 90022

Other trials in United States

About this study

Lower socioeconomic status (SES) individuals with type 1 diabetes have poorer outcomes than wealthier patients and part of this disparity comes from a lack of tools and knowledge about how to teach these patients on the technologies other patients take for granted. Therefore, this is a study designed to develop and test low literacy English/Spanish language teaching tools for patients with type 1 diabetes treated with varying types of technology in the Los Angeles County healthcare system. The aims are to:To reduce health disparities for underserved adults with diabetes on multiple daily injection (MDI) therapy using vials and syringes through the use of a simplified lower literacy, culturally and language appropriate approach to teach, implement and follow these individuals started on insulin pens and pumps/continuous subcutaneous insulin infusion (CSII); To show no increase in rates of diabetic ketoacidosis (DKA) or severe hypoglycemia when using CSII or pen therapy compared to baseline rates; To reduce time spent in hyper and hypoglycemic ranges, as well as glycemic variability, as measured by blinded continuous glucose monitoring (CGM); Reduce psychological distress due to diabetes and improve health-related quality of life, as measured by validated distress and quality of life scales. Secondary Aims include: Reduction in A1C levels with CSII/pen therapy compared to standard MDI treatment; and to perform a cost-analysis of the process of implementation to improve the generalizability of the model.

Read the detailed description

SUMMARY OF STUDY RATIONAL - Lower socioeconomic status (SES) individuals with type 1 diabetes (T1D) have poorer outcomes than wealthier patients and part of this disparity comes from a lack of tools and knowledge about how to teach these patients on the technologies other patients take for granted. Until recently many of these lower SES individuals did not have access to health insurance, but with the implementation of the Affordable Care Act the group with the greatest expansion of coverage is the young adult age group (ages 18 - 34), particularly in the Latino community. Increased insurance allows for access to newer technology including insulin pens and pumps. As these patients have not had access to such devices, low literacy educational tool are necessary for safe and efficient utilization. Therefore, this is a study designed to develop and test low literacy English/Spanish language teaching tools for patients with type 1 diabetes treated with varying types of technology in the Los Angeles County (LAC) healthcare system. This study is a single center pilot study and by the nature of our clinic setting it cannot be a randomized controlled trial - it is more of a naturalistic experiment comparing each patient to their prior state of glycemic control with their status after the educational intervention using low-literacy educational materials has been applied.

INTERVENTION - Baseline Visit: Participants will sign informed consent, complete questionnaires, and measure HbA1C. Those opting to do so will start a continuous glucose monitor (CGM) sensor. All patients will be provided the written low literacy teaching tools in the language of their choice.

CGM Visit - for those opting to wear CGM will occur at Week 2 where 14 days of CGM data will be downloaded from participants' device.

Education Sessions: Educational sessions will be conducted using the low-literacy tools we created. Classes will be available on Fridays during T1D Clinic and on Saturdays to maximize participation. Classes will be every two weeks for approximately 3 months. Classes will be approximately 1 ½ hours in duration. Patients will be encouraged but not required to attend the classes. However, those starting on the pen and/or pump will be asked to attend the relevant sessions to prepare them for use of the technology.

Educational Sessions:

Session 1 - Basics of type 1 management Session 2 - Carbohydrate counting, Session 3 - Insulin self- adjustment, Session 4 - Sick day rules and physical activity dose adjustments Session 5 - Starting the insulin pen (for pen users) or pump (for pump users) Session 6 - Trouble shooting the pump (for pump users)

Phone Calls - Each patient will be contacted monthly (baseline month up to month 3 visit) by the diabetes educator to follow-up on questions and concerns regarding their diabetes management.

Clinic Visit 2 - post education visit will occur at 3 months. Questionnaires will be administered, A1C measured and CGM data and compare to baseline.

Clinic Visit 3 - will occur at 6 months. Questionnaires will be administered, A1C measured and CGM data and compare to baseline.

Clinic Visit 4 -will occur at 12 months. Questionnaires will be administered, A1C measured and CGM data and compare to baseline and 6 months.

DATA COLLECTION AND TESTING PROCEDURES (Baseline, 6 months and 12 months) HbA1c - HbA1c will be obtained using the point of care Siemens DCA Vantage Analyzer.

Continuous Glucose Monitoring (CGM)- A commercially available DexCom G5 or Libre device will be provided and a sensor will be inserted. The participant will receive instructions on calibration, insertions, maintenance, use, and removal of the sensor.

T1D REDEEM Diabetes Distress Questionnaire- The T1D REDEEM Diabetes Distress Questionnaire measures several dimensions of stress related to having type 1 diabetes. It consists of the following 7 subscales: Subscale 1 - Powerlessness (5 items); Subscale 2 - Management Distress (4 items); Subscale 3 - Hypoglycemia Distress (4 items); Subscale 4 - Negative Social Perceptions (4 items); Subscale 5 - Eating Distress (3 items); Subscale 6 - Physician Distress (4 items); Subscale 7 - Friend/Family Distress (4 items). Each question has a 6-choice Likert response format. Administration time is approximately 10 minutes.

Hypoglycemia Fear Survey - The Hypoglycemia Fear Survey measures several dimensions of fear of hypoglycemia among adults with type 1 diabetes. It consists of a 10-item Behavior subscale that measured behaviors involved in avoidance and over-treatment of hypoglycemia and a 13-item Worry subscale that measures anxiety and fear surrounding hypoglycemia, each with a 5-choice Likert response format. Administration time is approximately 10 minutes.

Simplified Diabetes Knowledge Test -The Simplified Diabetes Knowledge Test consists of 23 knowledge test items developed by the Michigan Diabetes Research Training Center (MDRTC). These items represent a test of general knowledge of diabetes and are answered in a true/false/don't know format. The psychometric properties provide information regarding the reliability of the various groups of items, as well as a difficulty index (percent of patients who scored this item correctly), and an item to group total correlation for each item. These data can be reported when describing the use of the test. Administration time is approximately 15 minutes.

Assessment of Sever Hypoglycemia and Diabetic Ketoacidosis -The Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis is an interviewer administered survey assessing if the subject had any episodes of severe hypoglycemia and/or diabetic ketoacidosis since their last study visit. Events are recorded to assess frequency, as is type of assistance required to treat the event. Administration time is approximately 5 minutes.

Conditions
Type1diabetes
Being tested
Education: Session 1 - Basics of type 1 management, Session 2 - Carbohydrate counting, Education: Session 3 - Insulin self- adjustment, Education: Session 4 - Sick day rules and physical activity dose adjustments, Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)
Keywords
low-literacy, diabetes education

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Education: Session 1 - Basics of type 1 managementOther

    In a group education session, a diabetes educator provides educational session 1 - Basics of type 1 management.

    Accompanying educational guide:

    How Can I Manage My Type 1 Diabetes Better?

  • Session 2 - Carbohydrate countingOther

    In a group education session, a diabetes educator provides educational session 2 - Carbohydrate counting

    Accompanying educational guide:

    How Can I Manage My Type 1 Diabetes Better?

  • Education: Session 3 - Insulin self- adjustmentOther

    In a group education session, a diabetes educator provides educational session 3 - Insulin self- adjustment

    Accompanying educational guide:

    How Can I Manage My Type 1 Diabetes Better?

  • Education: Session 4 - Sick day rules and physical activity dose adjustmentsOther

    In a group education session, a diabetes educator provides educational session 4 - Sick day rules and physical activity dose adjustments

    Accompanying educational guide:

    How Can I Manage My Type 1 Diabetes Better?

  • Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)Other

    In a group education session, a diabetes educator provides educational session 5 - Starting the insulin pen (for pen users) or pump (for pump users)

    Accompanying educational guide:

    Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump? Is the Insulin Pen Right for Me?

  • Education: Session 6 - Trouble shooting the pump (for pump users)Other

    In a group education session, a diabetes educator provides educational session 6 - Trouble shooting the pump (for pump users)

    Accompanying educational guide:

    Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump?

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Low-literacy based education on HbA1c

    Number of patients with decreased HbA1c as measured by point of care HbA1c level from baseline to 12 months

    Measured: 12-months

  2. Low-literacy based education on hypoglycemia

    Number of patients with decreased hypoglycemia as measured by self report from baseline to 12 months

    Measured: 12 months

  3. Low-literacy based education on diabetic ketoacidosis

    Number of patients with decreased diabetic ketoacidosis as measured by self report from baseline to 12 months

    Measured: 12 months

  4. Low-literacy based education on diabetes distress

    Number of patients with decreased diabetes distress as measured by Type 1 Diabetes Reducing Distress and Enhancing Effective Management diabetes distress scale from baseline to 12 months

    Measured: 12 months

  5. Low-literacy based education on hypoglycemia fear

    Number of patients with decreased hypoglycemia fear as measured by the Hypoglycemia Fear Survey from baseline to 12 months

    Measured: 12 months

  6. Low-literacy based education on diabetes knowledge

    Number of patients with increased as measured by the Simplified Diabetes Knowledge Test from baseline to 12 months

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2020
  2. Study start1 Apr 2017
  3. Primary completion31 Oct 2019
  4. Study completion31 Jul 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
63 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04550585
Sponsor's protocol ID
STEPP-UP
Acronym
STEPP-UP
Status last verified
Apr 2023
First submitted
9 Sep 2020
Last updated
24 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Orrange S, Ruelas V, Peters AL. Specialized Technology Education for Pumps and Pens in Underserved Populations with Diabetes. Diabetes Technol Ther. 2022 Apr;24(4):268-275. doi: 10.1089/dia.2021.0265. Epub 2021 Dec 7.

    PubMed 34809482

Questions about this trial

What is this clinical trial studying?

An observational study of Type1diabetes, run by University of Southern California at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Low-literacy based education on HbA1c (time frame: 12-months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04550585, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in